咳喘宁胶囊联合孟鲁司特钠和布地奈德治疗儿童咳嗽变异性哮喘的临床研究  

Clinical study of Kechuanning capsule combined with montelukast sodium and budesonide in the treatment of children with cough variant asthma

作　　者：万志坚 李勇 夏海波 WAN Zhi-jian LI Yong XIA Hai-bo(Shenzhen City Nanshan District Xili People＇s Hospital Xinwei Community Center, Shenzhen 518055, China)

机构地区：[1]深圳市南山区西丽人民医院新围社康中心药房,518055

出　　处：《中国实用医药》2017年第25期12-14,共3页China Practical Medicine

摘　　要：目的探讨咳喘宁胶囊联合孟鲁司特钠和布地奈德在儿童咳嗽变异性哮喘临床治疗中的应用效果。方法 90例咳嗽变异性哮喘患儿作为研究对象,将其随机分为观察组和对照组,各45例。观察组给予咳喘宁胶囊+孟鲁司特钠+布地奈德治疗,对照组给予孟鲁司特钠+布地奈德治疗。观察比较两组患儿的治疗效果及肺功能改善情况。结果观察组患儿的治疗总有效率95.56%高于对照组的82.22%,差异有统计学意义(P<0.05)。观察组气喘、咳嗽、哮鸣音消失时间(3.42±0.65)、(3.96±0.84)、(7.12±1.25)d均短于对照组的(5.95±1.05)、(8.52±1.22)、(10.86±2.18)d,差异有统计学意义(P<0.05)。治疗后,两组患儿的肺功能得到显著的改善,其中观察组患儿的一秒用力呼气容积(FEV1)为(2.69±0.45)L、FEV1/用力肺活量(FVC)为(83.17±10.62)%、呼气峰值流速(PEF)为(83.57±15.73)L/min,均优于对照组的(2.05±0.49)L、(70.16±11.25)%、(72.81±12.17)L/min,差异具有统计学意义(P<0.05)。结论在儿童咳嗽变异性哮喘的临床治疗当中,孟鲁司特钠和布地奈德是良好的治疗药物,联合应用咳喘宁胶囊,能够进一步提升临床治疗效果,加快患儿的康复进程。Objective To investigate the application effect of Kechuanning capsule combined with montelukast sodium and budesonide in the treatment of children with cough variant asthma.Methods A total of 90 children with cough variant asthma as study subjects were randomly divided into observation group and control group,with 45 cases in each group.The observation group was treated with Kechuanning capsule ＋ montelukast sodium ＋ budesonide,and the control group was treated with montelukast sodium ＋ budesonide.Observation and comparison were made on treatment effect and improvement of lung function in two groups.Results The observation group had higher total treatment effective rate as 95.56% than 82.22% in the control group,and the difference was statistical significant（P〈0.05）.The observation group had shorter asthma,cough,wheeze disappearance time respectively as（3.42±0.65）,（3.96±0.84） and（7.12±1.25） d than（5.95±1.05）,（8.52±1.22） and（10.86±2.18） d in the control group,and their difference was statistical significant（P〈0.05）.After treatment,both groups had significantly improved lung function,and the observation group had better forced expiratory volume in 1 second（FEV1） as（2.69±0.45） L,FEV1/forced vital capacity（FVC） as（83.17±10.62）%,peak expiratory flow rate（PEF） as（83.57±15.73） L/min than（2.05±0.49） L,（70.16±11.25） % and（72.81±12.17） L/min in the control group.Their difference was statistical significant（P〈0.05）.Conclusion In the clinical treatment of children with cough variant asthma,montelukast sodium and budesonide are good therapeutic drugs,but combining with Kechuanning capsule can further enhance the clinical treatment effect and speed up the rehabilitation process in children.

关 键 词：咳喘宁胶囊 孟鲁司特钠 布地奈德 咳嗽变异性哮喘 

分 类 号：R725.6[医药卫生—儿科]